Does Pharmacological Treatment of ADHD in Adults Enhance Parenting Performance? Results of a Double-Blind Randomized Trial
Abstract
Objective This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. Methods Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/day) was determined for parents during a 3-week open-label titration, followed by a within-subjects trial of the acute impact of LDX and placebo on observable parent-child interactions. Two laboratory-based, parent-child interactions simulating typical family tasks (e.g., homework, joint play) were conducted within 2 weeks, once with the adult on a blinded optimal dose of LDX and once on placebo (phase I). Parents were then randomly assigned to continue blinded treatment with LDX or placebo for another month followed by a third interaction task (phase II) to assess the ongoing effects of LDX on parent-child interactions. The primary outcome was the change in rate of parenting behaviors coded during the parent-child interaction tasks. Secondary outcomes included observed rates of children's inappropriate behaviors during the laboratory tasks and changes in parental ADHD symptom severity (ADHD-Rating Scale). Results Twenty parents (67%) completed the trial. In phase I, medication was associated with a significant reduction in negative talk by parents (p = 0.0066, d = -0.47). There was a Medication × Task interaction (p = 0.0235) with a reduction in children's negativ…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a 12-month open-label extension, LDX produced greater clinical response and symptom improvement in patients with greater baseline symptom severity.
“This long-term extension study demonstrated LDX’s increased degree of clinical response and symptom improvement in patients with greater baseline symptom severity.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [34]
Patients from the short-term and long-term trials at study end point achieved clinical response (≥30% decrease in ADHD-RS-IV and CGI-I score of 1 or 2) in 78.9% to 88.4% and symptomatic remission (ADHD-RS-IV ≤18) in 64.0% to 72.1%.
“Patients from the short-term trial22 and the long-term trial28 at study end point demonstrated increased symptom improvement as noted by clinical response criteria achieved by 78.9% to 88.4% and symptomatic remission achieved by 64.0% to 72.1% of participants.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [34]
Cites
Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder
Pelham, W. E., & Fabiano, G. A. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701818681 · Cited by 917 · see citing works
Self-citationFaraone, S. V., & Glatt, S. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04902pur · Cited by 387 · see citing works
Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0903 · Cited by 218 · see citing works
Boggs, S. R., Eyberg, S. M., Edwards, D. L., Rayfield, A., Jacobs, J., Bagner, D., & Hood, K. K. (2005) · Child & Family Behavior Therapy · doi:10.1300/j019v26n04_01 · Cited by 210 · see citing works
Medori, R., Ramos-Quiroga, J. A., Casas, M., Kooij, J. J. S., Niemelä, A., Trott, G.-E., Lee, E., & Buitelaar, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.008 · Cited by 186 · see citing works
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-34 · Cited by 136 · see citing works
Spencer, T. J., Adler, L. A., Weisler, R. H., & Youcha, S. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0911 · Cited by 79 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Lenzi, F., Cortese, S., Harris, J., & Masi, G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.010 · Cited by 141 · see citing works
Wang, C. H., Mazursky-Horowitz, H., & Chronis-Tuscano, A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0474-8 · Cited by 39 · see citing works
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Najib, J., Wimer, D., Zeng, J., Lam, K. W., Romanyak, N., Paige Morgan, E., & Thadavila, A. (2017) · Journal of Central Nervous System Disease · doi:10.1177/1179573517728090 · Cited by 17 · see citing works
- Authors
- Waxmonsky, J. G., Waschbusch, D. A., Babinski, D. E., Humphrey, H. H., Alfonso, A., Crum, K. I., Bernstein, M., Slavec, J., Augustus, J. N., & Pelham, W. E.
- Affiliations
- Florida International University (US)
- Corresponding author
- Waxmonsky, James G.
- Venue
- CNS Drugs
- Published
- 2014-05-06
- Volume
- 28
- Issue
- 7
- Pages
- 665-677
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2023581591
- Cited by
- 26
- References
- 7
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 2
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Shire
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- lisdexamfetamine, adult ADHD, parental ADHD, parent-child interaction, parental behavior, ADHD medication, homework, parental praise, adverse drug reactions, dose titration
- MeSH terms
- Lisdexamfetamine Dimesylate, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Child, Preschool, Dextroamphetamine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Parent-Child Relations, Psychiatric Status Rating Scales, Severity of Illness Index, Parenting, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
